Company intelligence / Profile preview

Adverio Pharma

Ownership: Private
Development stage: Other

Overview

Adverio Pharma GmbH is primarily engaged in asserting and defending intellectual property rights related to pharmaceutical products. The company has been a plaintiff in multiple patent infringement litigations concerning drugs such as Adempas® (riociguat), indicating its role as an IP holder or licensor rather than a traditional R&D-driven biotech/pharma developer

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Consulting

Partnerships

Bayer AG/Bayer Healthcare Pharmaceuticals Inc. ("Adempas" NDA holder; likely partnership or licensing relationship due to shared interest/legal standing regarding patents for riociguat/admpemas, though not explicitly stated as a formal partnership.)

Beyond the preview

Go deeper on Adverio Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adverio Pharma.

Explore the full profile